中文摘要：

目的：以稳定（SD）期、增大〈20%的非小细胞肺癌（NSCLC）患者为对象,研究症状、KPS评分对疗效判定结果为＂稳定＂的再评价作用。方法：纳入住院的NSCLC患者,入组前应用RECIST肿瘤疗效评价属于增大的SD期,入组时按其症状及KPS评分稳定与恶化分为两组,连续对入组后10个月的症状、KPS及肿瘤大小进行记录,分析两组患者的肿瘤稳定（SD）及死亡情况。结果：共有26例NSCLC患者入组,12例患者研究期间症状及KPS稳定,生存患者多,SD期患者多;14例患者研究期间症状及KPS逐渐恶化,生存患者少,SD期患者少。结论：处于增大SD期的非小细胞肺癌,将症状、KPS的稳定与恶化作为标准,可能更有利于对患者的疗效做出更准确的判断。

英文摘要：

Objective： In order to stabilize （ SD ）non small cell lung cancer stage, the increase more than 20% （ NSCLC ）patients were as the object to study symptoms and KPS score on the curative effect determination results for evaluating stability. Method： NSCLC patients in hospital were selected. Evaluation before entering the group used RECIST and the tumor which belonged to increase SD was selected. According to the symptoms and KPS stability and degradation, the patients were divided into two groups, recording the symptoms, KPS and tumor size in 10 months continuously and analyzing the tumor stability （ SD ）and death of two groups. Result： A total of 26 cases of NSCLC patients were into groups. 12 patients＇ symptoms and KPS keeped stable during the study. There were more survival patients and the patients in stage of SD were more. 14 patients＇ symptom and KPS deteriorated gradually. There were few survival patients and the patients in stage of SD were few. Conclusion ： During the phase of increasing SD of NSCLC, taking the symptoms and KPS＇s stability and degradation as the standard may be more beneficial to make more accurate judgments about patients.